Pluristem Therapeutics Stock Price - PSTI

4.46
0.00 (0.00%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
Level 1 Starter
Monthly Subscription
for only
$15.87
VAT not included
Company Name Stock Ticker Symbol Market Type
Pluristem Therapeutics Inc PSTI NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.01 0.22% 4.46 4.35 4.46 4.41 4.45 19:04:39
Bid Price Ask Price Spread Spread % News
4.25 5.20 0.95 18.27% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
243 37,300 $ 4.40 $ 164,189 150,199 3.11 - 10.40
Last Trade Time Type Quantity Stock Price Currency
16:00:00 314 $ 4.46 USD

Pluristem Therapeutics Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 79.66M 17.86M $ -26.13M -29.02 - 1.72M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Pluristem Therapeutics News

Loading Messages....

Latest PSTI Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PSTI Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week3.905.173.87014.60377,2310.5614.36%
1 Month3.845.173.59244.24140,3140.6216.15%
3 Months3.325.173.324.01160,1931.1434.34%
6 Months3.875.173.113.9197,7330.5915.25%
1 Year10.1010.403.115.92291,952-5.64-55.84%
3 Years11.3021.203.1111.39327,249-6.84-60.53%
5 Years30.0032.803.1112.73280,179-25.54-85.13%

Pluristem Therapeutics Description

Pluristem Therapeutics Inc is a US-based company which acts as a developer of placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The lead indications are critical limb ischemia, recovery after surgery for femoral neck fracture, and acute radiation syndrome. The company operations are focused on the research, development, clinical trials and manufacturing of cell therapeutics and related technologies. Pluristem operates through the single business segment being Development of placenta-based cell therapy product.


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.